Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynaecol Obstet. 2018;143(Suppl 2):51–8. https://doi.org/10.1002/ijgo.12613.

Article  PubMed  Google Scholar 

WHO Classification of Tumours Editorial Board. World Health Organization classification of tumours.5th ed. Female genital tumours. IARC Press, Lyon; 2020.

Gockley AA, Rauh-Hain JA, del Carmen MG. Uterine leiomyosarcoma: a review article. Int J Gynecol Cancer. 2014;24(9):1538–42. https://doi.org/10.1097/IGC.0000000000000290.

Article  PubMed  Google Scholar 

Oliva E, Zaloudek CJ, Soslow RA. Mesenchymal tumors of the uterus. In: Kurman R, Hedrick Ellenson L, Ronnett B, editors. Blaustein’s Pathology of the female genital tract. Springer, Cham; 2019. https://doi.org/10.1007/978-3-319-46334-6_10

Gadducci A, Multinu F, De Vitis LA, Cosio S, Carinelli S, Aletti GD. Endometrial stromal tumors of the uterus: epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol Oncol. 2023;171:95–105. https://doi.org/10.1016/j.ygyno.2023.02.009. This is a recent review that discusses the relevant treatment options and therapeutic advances for endometrial stromal tumors.

Hoang L, Chiang S, Lee CH. Endometrial stromal sarcomas and related neoplasms: new developments and diagnostic considerations. Pathology. 2018;50(2):162–77. https://doi.org/10.1016/j.pathol.2017.11.086.

Article  CAS  PubMed  Google Scholar 

Tanner EJ, Toussaint T, Leitao MM Jr, Hensley ML, Soslow RA, Gardner GJ, Jewell EL. Management of uterine adenosarcomas with and without sarcomatous overgrowth. Gynecol Oncol. 2013;129(1):140–4. https://doi.org/10.1016/j.ygyno.2012.12.036.

Article  PubMed  Google Scholar 

Carroll A, Ramirez PT, Westin SN, Soliman PT, Munsell MF, Nick AM, Schmeler KM, Klopp AH, Fleming ND. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence. Gynecol Oncol. 2014;135(3):455–61. https://doi.org/10.1016/j.ygyno.2014.10.022.

Article  PubMed  PubMed Central  Google Scholar 

McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol. 2002;55(5):321–5. https://doi.org/10.1136/jcp.55.5.321.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zelmanowicz A, Hildesheim A, Sherman ME, Sturgeon SR, Kurman RJ, Barrett RJ, Berman ML, Mortel R, Twiggs LB, Wilbanks GD, Brinton LA. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol. 1998;69(3):253–7. https://doi.org/10.1006/gyno.1998.4941.

Article  CAS  PubMed  Google Scholar 

Kobayashi H, Uekuri C, Akasaka J, Ito F, Shigemitsu A, Koike N, Shigetomi H. The biology of uterine sarcomas: a review and update. Mol Clin Oncol. 2013;1(4):599–609. https://doi.org/10.3892/mco.2013.124.

Article  PubMed  PubMed Central  Google Scholar 

National Comprehensive Cancer Network (NCCN). Uterine Neoplasms (Version 1.2024). https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Accessed 4/1/2024.

Gracia M, Yildirim Y, Macuks R, Mancari R, Achimas-Cadariu P, Cusine-Lopez L, Novak Z, Dallaku K, Zapardiel I; SARCUT Study Group. Impact of perioperative characteristics on the recurrence risk and survival of patients with uterine leiomyosarcoma. Int J Gynaecol Obstet. 2023;163(3):868–874. https://doi.org/10.1002/ijgo.14998. This was a sub-analysis of the SARCUT study that aimed to examine peri-operative characteristics that are associated with survival outcomes in uLMS. They found that complete cytoreduction was the main prognostic factor influencing survival and that adjuvant chemotherapy and radiation had no survival or recurrence benefit.

Seagle BL, Sobecki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study. Gynecol Oncol. 2017;145(1):61–70. https://doi.org/10.1016/j.ygyno.2017.02.012. This is a retrospective NCDB study that examined prognostic factors associated with survival in uLMS. The findings included no observed survival benefit of lymphadenectomy or oophorectomy in early stage, uterine-confined uLMS and a survival benefit for chemotherapy in advanced, metastatic uLMS.

Wright JD, Tergas AI, Burke WM, Cui RR, Ananth CV, Chen L, Hershman DL. Uterine pathology in women undergoing minimally invasive hysterectomy using morcellation. JAMA. 2014;312(12):1253–5. https://doi.org/10.1001/jama.2014.9005.

Article  PubMed  PubMed Central  Google Scholar 

Mahnert N, Morgan D, Campbell D, Johnston C, As-Sanie S. Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications. Obstet Gynecol. 2015;125(2):397–405. https://doi.org/10.1097/AOG.0000000000000642.

Article  PubMed  Google Scholar 

Zhang W, Han Z, Li Z, Zheng Z, Wu X. Reoperation with total hysterectomy after incomplete surgery is helpful in patients with incidentally diagnosed uterine leiomyosarcoma. Gynecol Obstet Invest. 2021;86(4):408–14. https://doi.org/10.1159/000515895.

Article  PubMed  Google Scholar 

Singh N, Al-Ruwaisan M, Batra A, Itani D, Ghatage P. Factors affecting overall survival in premenopausal women with uterine leiomyosarcoma: a retrospective analysis with long-term follow-up. J Obstet Gynaecol Can. 2020;42(12):1483–8. https://doi.org/10.1016/j.jogc.2020.05.016.

Article  PubMed  Google Scholar 

Hinchcliff E, Rumpf J, Ratan R, Fleming ND, Jazaeri A, Fellman B, Meyer L, Soliman P. Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma. Gynecol Oncol. 2022;167(3):490–495. https://doi.org/10.1016/j.ygyno.2022.09.024. This is a retrospective cohort study that aimed to examine the impact of oophorectomy and ER/PR status in early-stage uLMS. The authors found no survival benefit in women who underwent oophorectomy despite hormone-receptor status and that ER/PR status was not independently associated with survival outcomes.

Giuntoli RL 2nd, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, Gostout BS. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003;89(3):460–9. https://doi.org/10.1016/s0090-8258(03)00137-9.

Article  PubMed  Google Scholar 

Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer. 2008;112(4):820–30. https://doi.org/10.1002/cncr.23245.

Article  PubMed  Google Scholar 

Nasioudis D, Mastroyannis SA, Latif NA, Ko EM, Haggerty AF, Kim SH, Morgan MA, Giuntoli RL 2nd. Role of lymphadenectomy for apparent early stage uterine sarcoma; a comprehensive analysis of the National Cancer Database. Surg Oncol. 2021;38:101589. doi: https://doi.org/10.1016/j.suronc.2021.101589. This is a retrospective NCDB study that examined women with early-stage uterine sarcoma with or without lymphadenectomy. They reported incidence of lymph node metastasis by subtype, which was rare in early-stage disease, and there was no apparent survival benefit of lymphadenectomy across subtypes.

Coronado PJ, Alonso-Espias M, Yildirim Y, Macuks R, Mancari R, Achimas-Cadariu P, Aniorte SM, Mitidieri M, Lambaudie E, Dubois N, Zapardiel I; SARCUT Study Group. Lymph node dissection in uterine leiomyosarcomas: A matched-pair study. Gynecol Oncol. 2023;174:28–33. https://doi.org/10.1016/j.ygyno.2023.04.007. This is a retrospective matched-pair analysis of uLMS by lymphadenectomy status and found no survival benefit by lymphadenectomy status.

Costales AB, Radeva M, Ricci S. Characterizing the efficacy and trends of adjuvant therapy versus observation in women with early stage (uterine confined) leiomyosarcoma: a National Cancer Database study. J Gynecol Oncol. 2020;31(3):e21. https://doi.org/10.3802/jgo.2020.31.e21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim SI, Choi CH, Kim K, Hong DH, Park JY, Kwon BS, Lee KH, Hong DG, Shin SJ, Park SI, Kim YH, Lee SH, Lee S, Hong JH, Lee JY, Kim YB, No JH, Suh DH. Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: a Korean multicenter study. J Obstet Gynaecol Res. 2020;46(2):337–46. https://doi.org/10.1111/jog.14171.

Article  CAS  PubMed  Google Scholar 

Vaz J, Tian C, Richardson MT, Chan JK, Mysona D, Rao UN, Powell MA, Shriver CD, Hamilton CA, Casablanca Y, Maxwell GL, Darcy KM. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities. Gynecol Oncol. 2020;157(1):121–30. https://doi.org/10.1016/j.ygyno.2019.12.008.

Article  PubMed  Google Scholar 

Chantharasamee J, Wong K, Potivongsajarn P, Qorbani A, Motamed N, Brackert S, Cohen J, Chmielowski B, Kalbasi A, Rao J, Nelson S, Singh A. Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma. Cancer Med. 2022;11(15):2906–12. https://doi.org/10.1002/cam4.4665.

Article  PubMed  PubMed Central  Google Scholar 

Takehara K, Yamashita N, Watanabe R, Teramoto N, Tsuda H, Motohashi T, Harano K, Nakanishi T, Tokunaga H, Susumu N, Ueda Y, Yokoyama Y, Saito T. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma. Gynecol Oncol. 2020;157(1):115–20. https://doi.org/10.1016/j.ygyno.2020.01.022.

Article  CAS  PubMed  Google Scholar 

Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, Tateo S, Franchi M, Jobsen JJ, Coens C, Teodorovic I, Vergote I, Vermorken JB; European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44(6):808–18. https://doi.org/10.1016/j.ejca.2008.01.019. This phase III trial (EORTEC 55874) demonstrated no benefit of adjuvant pelvic radiation in management of early-stage uterine sarcoma, influencing guidelines which do not recommend pelvic radiation for management of these tumors.

Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, Beecham J, Park R, Silverberg S. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol. 1985;3(9):1240–5. https://doi.org/10.1200/JCO.1985.3.9.1240.

Article  CAS  PubMed  Google Scholar 

Hensley ML, Wathen JK, Maki RG, Araujo DM, Sutton G, Priebat DA, George S, Soslow RA, Baker LH. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer. 2013;119(8):1555–61. https://doi.org/10.1002/cncr.27942.

Article  CAS  PubMed  Google Scholar 

Hensley ML, Enserro D, Hatcher H, Ottevanger PB, Krarup-Hansen A, Blay JY, Fisher C, Moxley KM, Lele SB, Lea JS, Tewari KS, Thaker PH, Zivanovic O, O'Malley DM, Robison K, Miller DS. Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for high-grade uterine leiomyosarcoma: a Phase III NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2018;36(33):JCO1800454. https://doi.org/10.1200/JCO.18.00454. This was a phase III trial (GOG 277) that aimed to evaluate multi-agent adjuvant chemotherapy in patients with early-stage uLMS. This international trial closed early due to poor accrual and standard of care remains observation after complete surgical resection in early-stage uLMS.

Leitao MM Jr, Zivanovic O, Chi DS, Hensley ML, O’Cearbhaill R, Soslow RA, Barakat RR. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. Gynecol Oncol. 2012;125(2):409–13. https://doi.org/10.1016/j.ygyno.2012.02.014.

Article  PubMed  Google Scholar 

Cybulska P, Sioulas V, Orfanelli T, Zivanovic O, Mueller JJ, Broach VA, Long Roche KC, Sonoda Y, Hensley ML, O’Cearbhaill RE, Chi DS, Alektiar KM, Abu-Rustum NR, Leitao MM Jr. Secondary surgical resection for patients with recurrent uterine leiomyosarcoma. Gynecol Oncol. 2019;154(2):333–7. https://doi.org/10.1016/j.ygyno.2019.05.015.

Article  PubMed  PubMed Central  Google Scholar 

Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18(10):1397–1410. https://doi.org/10.1016/S1470-2045(17)30622-8. This phase III trial found the two regimens of gemcitabine/docetaxel versus doxorubicin to be similarly effective, but with slightly higher rates of adverse events in gemcitabine/docetaxel, reaffirming their roles as two of the first-line systemic therapies for advanced-stage or metastatic soft-tissue sarcomas.

Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, Sabbatini P, Tong W, Barakat R, Spriggs DR. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20(12):2824–31. https://doi.org/10.1200/JCO.2002.11.050.

Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109(3):329–34. https://doi.org/10.1016/j.ygyno.2008.03.010.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2008;109(3):323–8. https://doi.org/10.1016/j.ygyno.2008.02.024.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, Selle F, Guillemet C, Weber B, Largillier R, Bertucci F, Opinel P, Duffaud F, Reynaud-Bougnoux A, Delcambre C, Isambert N, Kerbrat P, Netter-Pinon G, Pinto N, Duvillard P, Haie-Meder C, Lhommé C, Rey A. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol. 2013;24(4):1099–104. https://doi.org/10.1093/annonc/mds545.

Hensley ML, Miller A, O’Malley DM, Mannel RS, Behbakht K, Bakkum-Gamez JN, Michael H. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015;33(10):1180–5. https://doi.org/10.1200/JCO.2014.58.3781.

Tap WD, Wagner AJ, Schöffski P, Martin-Broto J, Krarup-Hansen A, Ganjoo KN, Yen CC, Abdul Razak AR, Spira A, Kawai A, Le Cesne A, Van Tine BA, Naito Y, Park SH, Fedenko A, Pápai Z, Soldatenkova V, Shahir A, Mo G, Wright J, Jones RL; ANNOUNCE Investigators. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on survival in patients with advanced soft tissue sarcomas: the ANNOUNCE Randomized Clinical Trial. JAMA. 2020;323(13):1266–1276.